Received Aug 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
Bexsero, interchangeability with Menquadfi; This non-serious case was reported by a other health professional via call center representative and described the occurrence of interchange of vaccine products in a patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included Meningococcal vaccine A/C/Y/W conj (tet tox) (Menquadfi) for prophylaxis. The patient's past medical history included splenectomy. In AUG-2024, the patient received Bexsero. On an unknown date, the patient received Menquadfi. On an unknown date, an unknown time after receiving Bexsero and Menquadfi, the patient experienced interchange of vaccine products (Verbatim: Bexsero, interchangeability with Menquadfi). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 13-AUG-2025 A patient received a booster dose for Bexsero on August 2024 because of a splenectomy. The patient was indicated another booster on August 2025 which had not been administered till the time of reporting, hcp asked information to make clinical decision. Later on the call mentioned Bexsero was given as a booster after the patient´s first normal schedule was with Menquadfi.
Medical History/Concurrent Conditions: Splenectomy